IQVIA Holdings Inc. (IQV)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
IQVIA Holdings Inc. (IQV) trades at $168.63 with AI Score 50/100 (Hold). IQVIA Holdings Inc. delivers advanced analytics, technology solutions, and clinical research services to the life sciences industry. Market cap: $28.62B, Sector: Healthcare.
Last analyzed: Feb 9, 2026IQVIA Holdings Inc. (IQV) Healthcare & Pipeline Overview
IQVIA Holdings Inc. (IQV) empowers the life sciences industry with advanced analytics, technology, and clinical research services, driving innovation and improved patient outcomes. With a global footprint and comprehensive solutions, IQVIA is a key partner for pharmaceutical, biotechnology, and healthcare companies seeking to navigate the complexities of modern healthcare.
Investment Thesis
IQVIA presents a notable research candidate due to its pivotal role in the rapidly evolving life sciences industry. The company's comprehensive suite of services, spanning technology, analytics, and clinical research, positions it as a strategic partner for pharmaceutical and biotechnology companies. With a market capitalization of $31.93 billion and a P/E ratio of 23.44, IQVIA demonstrates financial stability and growth potential. The company's strong profit margin of 8.3% and gross margin of 26.3% reflect efficient operations and value delivery. Key growth catalysts include the increasing demand for data-driven insights in healthcare, the expansion of virtual clinical trials, and the growing need for patient engagement solutions. IQVIA's established market presence, coupled with its innovative solutions, makes it well-positioned to capitalize on these trends and deliver long-term value to investors. The company's beta of 1.36 indicates higher volatility compared to the market.
Based on FMP financials and quantitative analysis
Key Highlights
- IQVIA operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
- The company serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies.
- IQVIA has a market capitalization of $31.93 billion.
- The company's P/E ratio is 23.44.
- IQVIA's profit margin is 8.3%.
Competitors & Peers
Strengths
- Comprehensive service offerings.
- Global presence and established market position.
- Extensive data assets and analytics capabilities.
- Strong relationships with pharmaceutical and biotechnology companies.
Weaknesses
- High dependence on the pharmaceutical industry.
- Exposure to regulatory changes and compliance risks.
- Potential for data breaches and privacy concerns.
- Competition from other large healthcare companies.
Catalysts
- Increasing demand for data-driven insights in healthcare.
- Expansion of virtual clinical trials.
- Growing need for patient engagement solutions.
- Potential strategic acquisitions and partnerships to expand service offerings.
Risks
- Economic downturns and healthcare spending cuts could reduce demand for IQVIA's services.
- Increased competition from new entrants and existing players in the healthcare industry.
- Technological disruptions and evolving customer needs could require significant investments in innovation.
- Adverse regulatory changes and compliance requirements could increase operating costs.
- Data breaches and privacy concerns could damage IQVIA's reputation and result in financial losses.
Growth Opportunities
- Expansion of Real-World Evidence (RWE) Solutions: The market for RWE is rapidly growing as healthcare providers and payers increasingly rely on real-world data to inform treatment decisions and optimize patient outcomes. IQVIA can leverage its extensive data assets and analytics capabilities to expand its RWE solutions, providing valuable insights to pharmaceutical companies and healthcare organizations. This market is projected to reach $2.5 billion by 2028, offering a significant growth opportunity for IQVIA. Timeline: Ongoing.
- Adoption of Virtual Clinical Trials: Virtual clinical trials are gaining traction due to their ability to reduce costs, improve patient recruitment, and accelerate drug development timelines. IQVIA can capitalize on this trend by expanding its virtual trial platform and services, enabling pharmaceutical companies to conduct clinical trials more efficiently and effectively. The virtual clinical trials market is expected to reach $10 billion by 2027. Timeline: Ongoing.
- Growth in Emerging Markets: Emerging markets, such as China, India, and Brazil, offer significant growth opportunities for IQVIA due to their expanding healthcare infrastructure and increasing demand for pharmaceutical products. IQVIA can leverage its global presence and expertise to penetrate these markets, providing its comprehensive suite of services to local pharmaceutical companies and healthcare providers. Timeline: Ongoing.
- Strategic Acquisitions and Partnerships: IQVIA can pursue strategic acquisitions and partnerships to expand its service offerings, enhance its technological capabilities, and strengthen its market position. By acquiring companies with complementary expertise and technologies, IQVIA can accelerate its growth and innovation. Timeline: Ongoing.
- Increased Demand for Data Analytics: The increasing volume and complexity of healthcare data are driving demand for advanced analytics solutions that can extract meaningful insights and improve decision-making. IQVIA can leverage its expertise in data analytics to develop innovative solutions that address the evolving needs of the healthcare industry. The healthcare analytics market is projected to reach $75 billion by 2029. Timeline: Ongoing.
Opportunities
- Expansion of real-world evidence solutions.
- Adoption of virtual clinical trials.
- Growth in emerging markets.
- Strategic acquisitions and partnerships.
Threats
- Economic downturns and healthcare spending cuts.
- Increased competition from new entrants.
- Technological disruptions and evolving customer needs.
- Adverse regulatory changes and compliance requirements.
Competitive Advantages
- Extensive data assets and analytics capabilities.
- Comprehensive suite of services spanning technology, analytics, and clinical research.
- Global presence and established market position.
- Strong relationships with pharmaceutical and biotechnology companies.
About IQV
Founded in 1982 and headquartered in Durham, North Carolina, IQVIA Holdings Inc. has evolved into a leading provider of advanced analytics, technology solutions, and clinical research services tailored for the life sciences industry. Originally known as Quintiles IMS Holdings, Inc., the company rebranded to IQVIA in November 2017, reflecting its focus on leveraging data and insights to drive healthcare advancements. IQVIA operates through three core segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers cloud-based applications, real-world evidence solutions, and strategic consulting services, providing clients with actionable insights to improve healthcare decision-making. The Research & Development Solutions segment delivers comprehensive clinical trial support, project management, and laboratory services, accelerating drug development processes. The Contract Sales & Medical Solutions segment focuses on healthcare provider and patient engagement, enhancing scientific strategy and medical affairs. IQVIA serves a diverse clientele, including pharmaceutical, biotechnology, device and diagnostic, and consumer health companies, with a global presence spanning the Americas, Europe, Africa, and the Asia-Pacific regions. The company's strategic collaboration with HealthCore, Inc. further strengthens its capabilities in real-world evidence generation and healthcare data analysis.
What They Do
- Provides advanced analytics to the life sciences industry.
- Offers technology solutions for healthcare providers and pharmaceutical companies.
- Conducts clinical research services for drug development.
- Delivers real-world evidence solutions to improve patient outcomes.
- Provides consulting services to optimize healthcare decision-making.
- Offers contract sales and medical solutions for pharmaceutical companies.
- Engages with healthcare providers and patients to improve healthcare delivery.
Business Model
- Generates revenue through technology and analytics solutions.
- Earns income from research and development services.
- Provides contract sales and medical solutions for pharmaceutical companies.
- Offers consulting services to healthcare organizations.
Industry Context
IQVIA operates within the dynamic and growing medical diagnostics and research industry, driven by increasing healthcare expenditures, technological advancements, and the rising prevalence of chronic diseases. The market is characterized by intense competition among companies offering clinical research services, data analytics, and technology solutions. IQVIA's position is strengthened by its comprehensive service offerings and global reach. The industry is witnessing a shift towards personalized medicine, data-driven healthcare, and virtual clinical trials, creating significant opportunities for companies like IQVIA to innovate and expand their market share. Competitors include A (Agilent Technologies), ALC (Alcon), CAH (Cardinal Health), GEHC (GE HealthCare), and HLN (Haleon), each vying for market share in specific segments of the healthcare industry.
Key Customers
- Pharmaceutical companies
- Biotechnology companies
- Device and diagnostic companies
- Consumer health companies
Financials
Chart & Info
IQVIA Holdings Inc. (IQV) stock price: $168.63 (+0.00, +0.00%)
Latest News
-
Insperity Stock Price Decreases 18% After Reporting Loss in Q4
Zacks · Feb 12, 2026
-
Gartner, Stellantis, And Novo Nordisk Are Among Top 10 Large Cap Losers Last Week (Feb. 2-Feb. 6): Are the Others in Your Portfolio?
benzinga · Feb 8, 2026
-
IQVIA Q4 Earnings Call Highlights
MarketBeat · Feb 7, 2026
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for IQV.
Price Targets
Wall Street price target analysis for IQV.
MoonshotScore
What does this score mean?
The MoonshotScore rates IQV's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Latest News
Common Questions About IQV (Healthcare)
What does IQVIA Holdings Inc. do?
IQVIA Holdings Inc. is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. The company operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. IQVIA helps pharmaceutical, biotechnology, device and diagnostic, and consumer health companies improve their performance, accelerate drug development, and enhance patient outcomes by leveraging its extensive data assets, analytics capabilities, and industry expertise. The company serves clients in the Americas, Europe, Africa, and the Asia-Pacific regions.
Is IQV stock worth researching?
IQV stock presents a mixed investment profile. The company's strong market position, comprehensive service offerings, and growth opportunities in areas like real-world evidence and virtual clinical trials are positive indicators. However, potential risks such as economic downturns, increased competition, and regulatory changes should be considered. With a P/E ratio of 23.44 and a profit margin of 8.3%, IQVIA demonstrates financial stability, but investors should carefully evaluate the company's valuation relative to its growth prospects and industry peers before making an investment decision. The absence of a dividend yield may deter some investors.
What are the main risks for IQV?
IQVIA faces several key risks, including economic downturns and healthcare spending cuts, which could reduce demand for its services. Increased competition from new entrants and existing players in the healthcare industry poses a threat to its market share. Technological disruptions and evolving customer needs could require significant investments in innovation. Adverse regulatory changes and compliance requirements could increase operating costs. Additionally, data breaches and privacy concerns could damage IQVIA's reputation and result in financial losses. These risks should be carefully considered by investors.
How does IQVIA make money?
IQVIA generates revenue through its three main operating segments. The Technology & Analytics Solutions segment earns revenue by providing cloud-based applications, real-world evidence solutions, and strategic consulting services. The Research & Development Solutions segment generates income from project management, clinical monitoring, and laboratory services. The Contract Sales & Medical Solutions segment earns revenue by providing healthcare provider and patient engagement services, as well as scientific strategy and medical affairs services. These segments collectively serve pharmaceutical, biotechnology, device and diagnostic, and consumer health companies, generating a diversified revenue stream for IQVIA.
Who are IQVIA's main competitors?
IQVIA operates in a competitive landscape with several key players. Competitors include Agilent Technologies (A), Alcon (ALC), Cardinal Health (CAH), GE HealthCare (GEHC), and Haleon (HLN). Each of these companies offers various services and solutions within the healthcare industry, ranging from analytical and diagnostic solutions to pharmaceutical distribution and consumer healthcare products. IQVIA differentiates itself through its comprehensive suite of services, global presence, and extensive data assets, but it faces ongoing competition from these and other companies in the market.
What are the key factors to evaluate for IQV?
IQVIA Holdings Inc. (IQV) currently holds an AI score of 50/100, indicating moderate score. Key strength: Comprehensive service offerings. Primary risk to monitor: Economic downturns and healthcare spending cuts could reduce demand for IQVIA's services. This is not financial advice.
How frequently does IQV data refresh on this page?
IQV prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven IQV's recent stock price performance?
Recent price movement in IQVIA Holdings Inc. (IQV) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Comprehensive service offerings. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Stock data pending update. All data based on information available as of 2026-02-09.